CA2361838A1 - Traitement du cancer par restauration de la fonction pp32 - Google Patents

Traitement du cancer par restauration de la fonction pp32 Download PDF

Info

Publication number
CA2361838A1
CA2361838A1 CA002361838A CA2361838A CA2361838A1 CA 2361838 A1 CA2361838 A1 CA 2361838A1 CA 002361838 A CA002361838 A CA 002361838A CA 2361838 A CA2361838 A CA 2361838A CA 2361838 A1 CA2361838 A1 CA 2361838A1
Authority
CA
Canada
Prior art keywords
cells
sequence
expression
normal
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361838A
Other languages
English (en)
Inventor
Jining Bai
Gary R. Pasternack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2361838A1 publication Critical patent/CA2361838A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le traitement ou la prévention de cancer par restauration de la fonction pp32 de cellules dépourvues d'activité ou d'expression pp32 normale. Le procédé assure cette restauration de pp32, par transfection des cellules avec de l'ADN exprimant la pp32 normale, par administration d'un inducteur de l'activité pp32, et/ou inhibition d'une phosphatase nucléaire inhibée par pp32.
CA002361838A 1999-02-03 2000-02-03 Traitement du cancer par restauration de la fonction pp32 Abandoned CA2361838A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11866799P 1999-02-03 1999-02-03
US60/118,667 1999-02-03
PCT/US2000/002656 WO2000045852A1 (fr) 1999-02-03 2000-02-03 Traitement du cancer par restauration de la fonction pp32

Publications (1)

Publication Number Publication Date
CA2361838A1 true CA2361838A1 (fr) 2000-08-10

Family

ID=22380017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361838A Abandoned CA2361838A1 (fr) 1999-02-03 2000-02-03 Traitement du cancer par restauration de la fonction pp32

Country Status (5)

Country Link
EP (1) EP1146909A4 (fr)
JP (1) JP2002536346A (fr)
AU (1) AU2751900A (fr)
CA (1) CA2361838A1 (fr)
WO (1) WO2000045852A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361795B2 (en) * 2006-12-26 2013-01-29 Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Hepatopoietin and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734022A (en) * 1990-08-01 1998-03-31 The Johns Hopkins University Antibodies to a novel mammalian protein associated with uncontrolled cell division
US5700821A (en) * 1996-07-30 1997-12-23 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
US5916749A (en) * 1996-12-13 1999-06-29 Incyte Pharmaceuticals, Inc. Human phosphatase inhibitor protein
WO1999029906A2 (fr) * 1997-12-12 1999-06-17 The Johns Hopkins University Famille de genes possedant une activite de modulation de la transformation

Also Published As

Publication number Publication date
EP1146909A4 (fr) 2004-12-29
WO2000045852A1 (fr) 2000-08-10
AU2751900A (en) 2000-08-25
JP2002536346A (ja) 2002-10-29
EP1146909A1 (fr) 2001-10-24

Similar Documents

Publication Publication Date Title
US6740523B2 (en) 14-3-3σ arrests the cell cycle
ES2397441T3 (es) Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
JP2006512908A (ja) 腫瘍抑制遺伝子および組成物ならびにその作製法および使用法
JP3633616B2 (ja) 転写因子ｄｐ−１
JPH10507343A (ja) 網膜芽細胞腫タンパク質相互作用性ジンクフィンガータンパク質
JP2002525081A (ja) 低酸素により調節される遺伝子転写に特徴的な配列
US6930175B1 (en) Gene family with transformation modulating activity
JP2005500803A (ja) 破骨細胞関連レセプター
EP1045926B1 (fr) Famille de genes possedant une activite de modulation de la transformation
KR20090060212A (ko) 암의 검출 및 치료를 위한 조성물 및 방법
CA2361838A1 (fr) Traitement du cancer par restauration de la fonction pp32
AU2003204082B2 (en) Gene family with transformation modulating activity
US20060160103A1 (en) Mammalian neuralized family transcriptional regulators and uses
US6361954B1 (en) Methods of immunoassay for human CDC6
US7462447B2 (en) Methods for evaluating susceptibility to a bone homeostasis disorder
AU2005200892A1 (en) Method of treating cancer by restoration of PP32 function
AU4373599A (en) Human homologue of unc-53 protein of (c. elegans)
EP1151094A1 (fr) Traitement du cancer du col de l'uterus
WO1999035159A1 (fr) Oncogene et oncoproteine de lymphome/leucemie, ainsi que leurs procedes d'utilisation
CA2419851A1 (fr) Demonstration genetique du besoin de nkx6.1, nkx2.2 et nkx6.2 pour la production de neurones ventraux
WO2008075713A1 (fr) Marqueur pour le diagnostic du cancer et molécule cible pour une thérapie
CA2374678A1 (fr) Diagnostic, pronostic et traitement de cancers en rapport avec le gene barx2
WO2001018037A2 (fr) Proteine induite par p53 avec un domaine de mort pouvant favoriser l'apoptose
JPH10127296A (ja) Ｅｘｔ２遺伝子
US20040053210A1 (en) Genetic demonstration of requirement for nkx6.1, nkx2.2 and nkx6.2 in ventral neuron generation

Legal Events

Date Code Title Description
FZDE Dead